| (Values in U.S. Thousands) | Nov, 2025 | Nov, 2024 | Nov, 2023 | Nov, 2022 | Nov, 2021 |
| Sales | 31,570 | 31,990 | 31,340 | 30,340 | 28,880 |
| Sales Growth | -1.31% | +2.07% | +3.30% | +5.06% | -7.29% |
| Net Income | -2,430 | 400 | -9,520 | 2,770 | 2,080 |
| Net Income Growth | -707.50% | +104.20% | -443.68% | +33.17% | -42.54% |
Cryo-Cell Intl Inc (CCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CRYO-CELL International is engaged in cryogenic cellular storage and the design and developmentof cellular storage devices. They currently focus on the processing and preservation of umbilical cord blood stem cells for autologous/sibling use. They have pioneered several technologies that allow for the processing and storage of specimens in a cryogenic environment, and presently, their mission of affordability for U-Cord blood preservation remains in effect.
Fiscal Year End Date: 11/30